Jagtap Nitin, Bhakhar Pintu, Miftahussurur Muhammad, S Yashavanth H, Shrimal Pankaj, Sharma Mithun, Gupta Rajesh, Rao P N, Reddy D Nageshwar
Department of Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad 500082, India.
Acta Med Indones. 2021 Jan;53(1):24-30.
alcohol may have additional neurotoxic ill-effects in patients with alcohol related cirrhosis apart from hepatic encephalopathy. We aimed to evaluate minimal hepatic encephalopathy (MHE) with Psychometric Hepatic Encephalopathy (PHES) score and Critical Flicker Frequency (CFF) in alcohol (ALD) and non-alcoholic steatohepatitis related (NASH) related cirrhosis.
398 patients were screened between March 2016 and December 2018; of which 71 patients were included in ALD group and 69 in NASH group. All included patients underwent psychometric tests which included number connection test A and B (NCT-A and NCT-B), serial dot test (SDT), digit symbol test (DST), line tracing test (LTT) and CFF. MHE was diagnosed when their PHES was <-4.
the prevalence of MHE was significantly higher in ALD group compared to NASH (69.01% vs 40.58%; P=0.007). The performance of individual psychometric tests was significantly poorer in ALD (P<0.05). Overall sensitivity and specificity of CFF was 76.62% (95%CI 65.59 - 85.52) and 46.03% (95%CI 33.39 - 59.06) respectively. Mean CFF was significantly lower in ALD than NASH (37.07 (SD 2.37) vs 39.05 (SD 2.40), P=0.001); also in presence of MHE (36.95 (SD 2.04) vs 37.96 (SD 1.87), P=0.033) and absence of MHE (37.34 (SD 3.01) vs 39.79 (SD 2.46), P=0.001).
MHE is significantly more common in patients with ALD cirrhosis than NASH counterparts. Overall CFF values are less in alcohol related cirrhosis than NASH related cirrhosis, even in presence or absence of MHE. We recommend additional caution in managing MHE in ALD cirrhosis.
除肝性脑病外,酒精可能对酒精性肝硬化患者产生额外的神经毒性不良影响。我们旨在通过心理测量肝性脑病(PHES)评分和临界闪烁频率(CFF)评估酒精性肝病(ALD)和非酒精性脂肪性肝炎相关性(NASH)肝硬化患者的轻微肝性脑病(MHE)。
2016年3月至2018年12月期间对398例患者进行了筛查;其中71例患者纳入ALD组,69例纳入NASH组。所有纳入患者均接受了心理测量测试,包括数字连接测试A和B(NCT - A和NCT - B)、连续点测试(SDT)、数字符号测试(DST)、线追踪测试(LTT)和CFF。当患者的PHES< - 4时诊断为MHE。
ALD组MHE的患病率显著高于NASH组(69.01%对40.58%;P = 0.007)。ALD组个体心理测量测试的表现明显较差(P<0.05)。CFF的总体敏感性和特异性分别为76.62%(95%CI 65.59 - 85.52)和46.03%(95%CI 33.39 - 59.06)。ALD组的平均CFF显著低于NASH组(37.07(标准差2.37)对39.05(标准差2.40),P = 0.001);在存在MHE(36.95(标准差2.04)对37.96(标准差1.87),P = 0.033)和不存在MHE(37.34(标准差3.01)对39.79(标准差2.46),P = 0.001)的情况下也是如此。
ALD肝硬化患者中MHE比NASH肝硬化患者明显更常见。即使存在或不存在MHE,酒精性肝硬化患者的总体CFF值也低于NASH相关性肝硬化患者。我们建议在管理ALD肝硬化患者的MHE时格外谨慎。